Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Open-Label Randomized Trial - Takeaways - MDSpire

Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Open-Label Randomized Trial

  • By

  • Yuan Chang

  • Gongfeng Tang

  • Haixuan Wu

  • Xuelei Liang

  • Yi Liu

  • Fenglin Zhuo

  • February 13, 2026

  • 0 min

Share

  • 1

    Moderate-to-severe chronic hand eczema significantly affects patients' quality of life and poses a socioeconomic burden.

  • 2

    Benvitimod is a novel nonsteroidal topical agent that shows promise in treating moderate-to-severe chronic hand eczema.

  • 3

    The study compares the efficacy and safety of benvitimod and halometasone in patients with moderate-to-severe chronic hand eczema.

  • 4

    Benvitimod demonstrated similar efficacy to halometasone but with a more favorable safety profile.

  • 5

    This research highlights the need for innovative treatments for patients resistant to or refusing traditional corticosteroid therapies.

Original Source(s)

Comparative Analysis of Efficacy and Safety Between Benvitimod and Halometasone in Individuals with Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Open-Label Randomized Trial

  • by Yuan Chang, Gongfeng Tang, Haixuan Wu, Xuelei Liang, Yi Liu, Fenglin Zhuo

  • February 13, 2026

Related Content

Medical Oddities: Muscle Memory Before Birth? 

When dad trains offspring gain, bar tricks can end in the OR, guts that linger, empathetic pain, and “natural” immune traps this week.

Top 10 Evidence-Based Essentials in Dermatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.